Nepsis Inc. Buys Shares of 88,696 Medtronic PLC $MDT

Nepsis Inc. acquired a new stake in Medtronic PLC (NYSE:MDT) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 88,696 shares of the medical technology company’s stock, valued at approximately $8,520,000. Medtronic makes up about 2.6% of Nepsis Inc.’s holdings, making the stock its 22nd biggest holding.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MDT. Delos Wealth Advisors LLC bought a new position in shares of Medtronic in the second quarter worth about $27,000. Corundum Trust Company INC acquired a new stake in shares of Medtronic in the 3rd quarter valued at approximately $27,000. Valley Wealth Managers Inc. bought a new stake in shares of Medtronic during the 3rd quarter valued at approximately $29,000. Board of the Pension Protection Fund acquired a new position in Medtronic during the 4th quarter worth approximately $29,000. Finally, GoalVest Advisory LLC acquired a new position in Medtronic during the 4th quarter worth approximately $29,000. Institutional investors own 82.06% of the company’s stock.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA clearance expands addressable market for Stealth AXiS — The U.S. FDA cleared Medtronic’s Stealth AXiS surgical system for cranial and ENT procedures, adding to the spine clearance received in February. The broader indication increases the platform’s market opportunity for navigation + robotics in higher‑value neurosurgical/ENT cases, supporting future procedure volume and device sales. Medtronic gets US FDA nod to use surgical system in cranial, ENT surgeries
• Positive Sentiment: Distribution deal adds a minimally invasive pain product to the portfolio — Medtronic expanded distribution with Merit Medical for the ViaVerte™ basivertebral nerve ablation (BVNA) system, a minimally invasive, implant‑free therapy for chronic low back pain. This is a commercially relevant, non‑capital product that could contribute recurring revenue and broaden Medtronic’s spine/pain offerings. Medtronic (MDT) Expands Partnership with Merit Medical for ViaVerte System
• Positive Sentiment: Analyst reaffirmation with a high price target — Needham reiterated a Buy rating and $120 price target on MDT, signaling continued analyst confidence in Medtronic’s multi‑year growth thesis (including tuck‑ins, robotics, and margin improvement). That target implies substantial upside from current levels and can support investor sentiment. Needham Reiterates Buy Rating on Medtronic
• Positive Sentiment: Strategic spin‑off plan remains a potential value catalyst — Coverage highlights Medtronic’s planned spin‑off of its high‑growth diabetes unit later this year. A diabetes spin‑off could unlock value for the parent (focused on cardiovascular, robotics, and other higher‑margin hospital businesses) and make both entities more strategically coherent. 5 Spin-Off Stocks That Could Reward Patient Investors in 2026
• Neutral Sentiment: Investor writeups argue the company is set for faster growth — Recent commentary (e.g., Seeking Alpha’s “Time For A Growth Spurt”) lays out a bullish case around robotics, procedure growth, and margin leverage; these are thematic/analytical pieces rather than direct catalysts. Impact timing is uncertain. Medtronic: Time For A Growth Spurt
• Negative Sentiment: Near‑term technicals and volume suggest selling pressure — MDT is trading below its 50‑ and 200‑day moving averages with intraday volume above average, a setup that can keep the stock under pressure despite positive fundamental news until technicals stabilize.

Medtronic Trading Down 0.5%

Shares of NYSE MDT opened at $87.20 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The firm has a 50 day moving average price of $95.80 and a two-hundred day moving average price of $96.48. The stock has a market cap of $111.96 billion, a P/E ratio of 24.29, a price-to-earnings-growth ratio of 2.25 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Wells Fargo & Company started coverage on shares of Medtronic in a research report on Friday, January 30th. They issued an “overweight” rating and a $114.00 target price on the stock. Daiwa Securities Group lowered their price target on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, February 27th. Mizuho upgraded Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. Leerink Partners reissued an “outperform” rating and set a $119.00 price objective on shares of Medtronic in a report on Tuesday, March 10th. Finally, Piper Sandler restated a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).